Millennium Pushing Ahead With Velcade In Non-Hodgkins Lymphoma
This article was originally published in The Pink Sheet Daily
Executive Summary
NHL population represents a greater opportunity than all multiple myeloma settings combined, CEO Dunsire says during business update.
You may also be interested in...
Velcade Wins FDA Clearance In First-Line MM
Agency hits PDUFA date with “quite broad” new label, exec tells “The Pink Sheet” DAILY.
Velcade Wins FDA Clearance In First-Line MM
Agency hits PDUFA date with “quite broad” new label, exec tells “The Pink Sheet” DAILY.
sNDA Puts Velcade Ahead of Revlimid in Race To First-Line Multiple Myeloma Market
If FDA grants priority review, a decision for Millenium’s product could come as early as mid-2008.